News & Press

Adopting Virtual Tools in COVID-19 New Normal

Edition 2 / June 2020
Editorial > CordenPharma Navigates COVID-19 Towards “The New Normal”

Edition 2 / June 2020

Share:
Mike Ironside, Interim Head of Development & Project Management of CordenPharma, headshot

Author
Stephen Houldsworth,

VP, Global Head of Platform Management & Marketing,
CordenPharma International


CordenPharma Navigates COVID-19 Towards “The New Normal”

Dr. Stephen Houldsworth, VP, Global Head of Platform Management & Marketing, CordenPharma International discusses the changing realities for CordenPharma and the Pharma Industry in the face of the COVID-19 pandemic. Please submit your questions or feedback here.

Video Transcript

CordenPharma’s Approach to COVID-19

Welcome to the Second Quarter, Corden Connect newsletter. My name is Stephen Houldsworth, and I’m the VP of Platform Management & Marketing for CordenPharma International. The last time we connected with you all, the world was just beginning to understand the impact COVID-19 was going to have on our lives. Our last newsletter was released just prior to the cancellation of DCAT in March. And since then, we have seen our lives literally turned upside down. No one could’ve predicted what we’ve seen occur over the last three months. Who could have imagined the closing of international borders and complete shutdown of business travel, for example?

Within Corden Pharma, we’ve been working diligently on a daily basis to keep our operations moving forward, to ensure that we could continue to deliver the life saving treatments that we manufacture on behalf of our customers.

Our Amazing Workforce

We have an absolutely amazing workforce that has continually operated above and beyond the call of duty to maintain research & development, analytical and manufacturing operations, as well as develop some truly amazing out-of the-box ideas to help our local communities.

Hopefully, you’ve been following our Linkedin posts detailing some of the site activities during these trying times. But if not, don’t worry, we have you covered. At the end of the newsletter we’ve included links to all of these posts and videos.

A New Video Editorial Approach

With this second quarterly Newsletter, and in-line with how the world has changed so dramatically over the last three months, we decided to mix things up a little bit by breaking our historically text-driven newsletter to bring you this (hopefully) short video editorial.

I think we’re now all learning new skills, especially around video conferencing. So how better to share in this journey than to jump into this video editorial?

Adapting to COVID-19’s Virtual New Normal

As we move forward dealing with the realities of our “new normal,” video and visual communication will become a new focus for our organization while we attempt to replace the face-to-face interactions that were such an important aspect of our role as a world-class CDMO.

To that end, our marketing team are creating new videos to highlight our platform capabilities and manufacturing sites. We’re gearing up to create virtual tours of our facilities, and have already begun to accept virtual audits at our sites. And finally, in the coming months, we’ll be looking to initiate a number of virtual events involving key staff members from within the organization, to showcase our experts.

So Now, Onto the Actual Corden Connect Q2 2020 Newsletter..

This quarter we have three great articles to share with you. Firstly, Jason Bertola, our Director of the Highly Potent & Oncology Platform, will overview the very latest from his platform. This will include a high-level overview of a new white paper that a very talented development team at CordenPharma Plankstadt prepared, taking a look at pediatric dosage form considerations for highly potent compounds.

The second and third articles are very timely COVID-19 pieces. First up is how CordenPharma ourselves have adapted to the new challenges that COVID-19 has thrown at us. Written by our VP, Global Head of Sales & Key Account Management, Dr. Mimoun Ayoub, he details not only how the manufacturing sites have adjusted to the new normal, but also how we have shifted to create capacity to service our customers changing needs, and where we go from here.

And this is followed by a general review of the pharmaceuticals industry’s response to the COVID-19 pandemic, prepared by Dr. Mike Ironside, Interim Head of Developing, Manufacturing & Project Management for CordenPharma. Here, Mike reviews how the industry has mobilised to treat the great unmet need, looking at both treatments and cures targeted towards COVID-19.

I hope you all enjoy the newsletter this quarter and learn something new. We’re always open to your suggestions for future topics. You can either provide them directly to your Key Account Manager, or via the feedback link shown below this video.

While we’re on the subject of feedback, your feedback would be greatly appreciated as to whether you enjoyed the video style this month, and whether you’d like to see this repeated in the future.

And with that, I will conclude our first video editorial. Wishing you all good health and looking forward to meeting you all at a tradeshow or conference sometime in the future. Be safe, and thank you!


Subscribe to our Newsletter

Stay up to date with the latest thought leadership articles and news from CordenPharma.